pharma

YOU MIGHT BE INTERESTED IN

Global Pain Relieving Drug Market Analysis 2010-2025
In 2009, the global pain relieving drug market generated revenues over $50bn. From 2010, that sector will benefit from new drugs and reformulations of existing products. Cases of pain from many conditions are increasing rapidly. Worldwide, the treatment of pain is a priority for healthcare providers, with high demand for drugs. Where is the pain relieving drug market heading - technologically and commercially - from 2010 onwards?
...more details
The Global Pain Market, 2008-2023
The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you.
...more details
World Neurodegenerative Diseases Market 2009-2024
The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards.
...more details
The World Dermatological Market Outlook 2010-2024
The dermatological drug market continues to be important and competitive globally. New treatments for skin disorders and increasing disease prevalence will lead to further expansion of that market area, we predict. There are potential gains in all the main aspects of pharma development: novel drugs, drug delivery innovation, generics and biotechnology. Our brand new report - The World Dermatological Market Outlook 2010-2024 - explains why that market will expand, revealing where the most-exciting developments will lie during our forecast period. And how you can benefit from this expansion.
...more details
The World Antibacterial Treatments Market 2010-2024
Our latest report examines the prospects for antibacterial treatments worldwide from 2009 to 2024, including detailed sales forecasts for leading products in that sector. The global anti-infectives market generated revenues of $79bn for the 12 months to the second-quarter of 2009, of which the antibacterial market accounted for $37bn. How will this market perform from 2010 onwards? Our original forecasts and qualitative analyses will show you how the antibacterial sector will fare, pointing out the most-exciting and fast-growing areas.
...more details
The Global OTC Pharmaceutical Market 2009-2024
General economic trends worldwide will affect the over-the-counter (OTC) pharma market from 2009 onwards, with both market restraints and opportunities present. In this new report visiongain notes that Rx-to-OTC switching and the continuing importance of emerging pharma markets will drive OTC sales growth from 2009 onwards. Our forecasts reveal that the OTC pharma market will grow significantly next decade. This report explains where future OTC switching will occur, providing you with the information that you need to understand the current OTC market and its future prospects. The potential of this market remains significant, despite general economic uncertainty, visiongain asserts.
...more details
The Global Rheumatoid Arthritis Market Forecasts to 2012
In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to Q3 2006, from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics was in the order of $16bn worldwide.
...more details

REPORT

...see all

The Global Analgesics Market 2009-2024

Download report Download sample

Publication date: 14/10/2009
Number of Pages: 128

Report Details
Table of Contents
Companies Listed

Report Details

Where will the main commercial opportunities lie in the treatment of pain from the present onwards? Our new pharma report explains in depth, giving you the answers that you require.

There remain many unmet therapeutic needs in the treatment of pain, as well as high demand for analgesic treatments worldwide. For several types of pain, including conditions such as diabetic neuropathy and sciatica, there are currently few treatments. Furthermore, the pain sector is associated with side effects. Novel compounds that demonstrate improved safety profiles - combined with high efficacies - have the potential to gain significant market shares from 2009 onwards. At the same time, high regulatory hurdles - in particular those following the Vioxx withdrawal - could restrict market entry. Nevertheless, there remain high potential revenues to be made in this sector from 2009 to 2024, as our new report explains.

Continued high prevalence of pain worldwide, driven by an increase in the many disorders with pain as a symptom, drives the market. Furthermore, intensive R&D - with a solid current pipeline - will make the analgesics market dynamic and commercially promising in the years ahead. There is also rapidly-increasing demand for pain treatments in developing countries. Our new report - The Global Analgesics Market 2009-2024 – explains how this market will develop, and where the main opportunities will lie during our forecast period.

This report addresses the following therapeutic categories in detail:
• Non-narcotics and anti-pyretics
• Narcotics
• Anti-rheumatic drugs
• Anti-migraine drugs
• Anti-epileptic drugs
• Local anaesthetics.

The Global Analgesics Market 2009-2024 provides detailed forecasts for all six categories, as well as for individual products in each category. What types of therapeutic agents are likely to enter the market from 2009 onwards, and will they hold the potential to dominate? Where do the main opportunities lie, and what are the principal threats in this market area? This report will provide you with the analytical information that you need to understand current trends and future directions in the global analgesics market. We discuss prospects for the following products in detail (by category):

• Non-narcotics and anti-pyretics
- Tylenol
- Advil
- Aspirin Bayer
- Panadol
• Narcotics
- Oxycontin
- Duragesic
- Fentanyl Myla
• Anti-rheumatic drugs
- Celebrex
- Voltaren
• Anti-migraine drugs
- Imigran
- Maxalt
• Anti-epileptic drugs
- Lyrica
• Local anaesthetics
- Lidoderm

Novel therapeutics and other developments - such as Rx/Dx strategies, monoclonal antibodies and anti-abuse technologies - are included in the pipeline sections of this report.

Comprehensive analysis of the market area

The Global Analgesics Market 2009-2024 examines this market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. There are over 60+ tables and figures plus comprehensive expert interviews. This report provides detailed sales forecasts, discussions of pipeline developments and relevant commercial drivers and restraints. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, we apply rigorous financial forecasting, qualitative analyses and the assessments of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion to benefit your work.

Why you should buy The Global Analgesics Market 2009-2024

In this report you will receive the following benefits, in particular:
• You will assess the current market for analgesic therapeutics
• You will review the overall analgesic therapeutics market, including a global sales forecast for 2009 to 2024
• You will receive sales forecasts for analgesic submarkets from 2009 to 2024, with detailed discussions
• You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2009 to 2024, with discussions
• You will examine commercial drivers and restraints in depth
• You will discover the most-exciting pipeline developments in the sector, with informed commentary to give you foresight
• You will discover expert opinions from our original survey of the sector, with full interview transcripts provided.

You can obtain this report today

Nobody with an interest in the analgesics field can afford to overlook this new market study. We predict that total revenues in the analgesics market will increase throughout the forecast period 2009 to 2024. Continued and increasing prevalence of the conditions, coupled with high associated economic costs, give this market great potential from 2009 onwards. Do you want to know more? You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Executive Summary
1.1 Aims of This Report
1.2 Chapter Breakdown

2. Introduction - Definition of Pain
2.1 Physiology of Pain
2.1.1 Signal Transmission
2.1.2 Endogenous Analgesics
2.2 Social and Financial Impact of Pain
2.3 Classification and Types of Pain
2.3.1 Acute Pain and Chronic Pain
2.4 Nociceptive pain
2.5 Neuropathic Pain
2.6 Psychogenic Pain
2.7 Treatment Options
2.7.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) and Para-acetylaminophenol
2.7.2 Opioids
2.7.3 Tricyclic Antidepressants and Anticonvulsants
2.8 Defining the Severity of Pain

3. Introduction - The OTC Factor
3.1 Key Features of OTC Pharmaceuticals
3.2 OTC Switching
3.3 OTC Regulation
3.4 The OTC Analgesics Market
3.4.1 Systemic Analgesics
3.4.2 External Analgesics

4. The Global Analgesics Market 2009-2024
4.1 Analysis of the Current Market
4.1.1 Leading Categories in the Analgesics Market
4.1.2 Blockbusters in the Analgesics Market
4.2 Forecast for the Global Analgesics Market 2009-2024
4.3 Assessment of the OTC Proportion of the Market
4.4 Concluding Remarks

5. The Non-Narcotics and Anti-Pyretics Market 2009-2024
5.1 Analysis of the Current Market
5.2 Forecast for the Non-Narcotics and Anti-Pyretics Market 2009-2024
5.3 Tylenol
5.3.1 Tylenol Sales Forecast 2009-2024
5.3.2 A Billion Dollar OTC Brand
5.4 Advil
5.4.1 Advil Sales Forecast 2009-2024
5.5 Aspirin Bayer
5.5.1 Aspirin Bayer Sales Forecast 2009-2024
5.6 Panadol
5.6.1 Panadol Sales Forecast 2009-2024
5.6.2 Targeting Emerging Markets
5.7 Concluding Remarks

6. The General Narcotics Market 2009-2024
6.1 Analysis of the Current Market
6.2 Forecast for the Narcotics Market 2009-2024
6.3 Oxycontin
6.3.1 Patent Issues
6.3.2 Controversies
6.4 Duragesic
6.4.1 Safety Issues and Risk Management Plans
6.5 Fentanyl Myla
6.5.1 Competition and Safety Concerns
6.6 Concluding Remarks

7. The Anti-Rheumatics Pain Relief Market 2009-2024
7.1 Analysis of the Current Market
7.2 Forecast for the Anti-Rheumatics Pain Relief Market 2009-2024
7.2.1 Safety Issues for COX-2 Inhibitors
7.3 Celebrex
7.4 Voltaren
7.4.1 Surviving Patent Expiry: An OTC Success Story So Far
7.4.2 Growth in Emerging Markets
7.5 Concluding Remarks

8. The Anti-Migraine Market 2009-2024
8.1 Causes of Migraine
8.1.1 Triggers of Migraine Headaches
8.1.2 Treatment Options
8.2 Analysis of the Current Market
8.3 Forecast for the Anti-Migraine Market 2009-2024
8.4 Imigran
8.5 Maxalt
8.6 Competition in the Anti-Migraine Market
8.7 Future Directions and Concluding Remarks

9. The Anti-Epilepsy Market 2009-2024
9.1 The Physiology and Treatment of Epilepsy
9.2 Analysis of the Current Market
9.3 Forecast for the Anti-Epilepsy Market 2009-2024
9.4 Lyrica
9.5 Concluding Remarks

10. The Local Anaesthetics Market 2009-2024
10.1 Analysis of the Local Anaesthetics Market
10.2 Forecast for the Local Anaesthetics Market 2009-2024
10.3 Lidoderm
10.3.1 Competition for Lidoderm
10.4 Concluding Remarks

11. SWOT Analysis
11.1 Market Drivers
11.1.1 Personalised Therapy
11.1.2 Increasing Prevalence
11.1.3 Products with Several Indications
11.2 Market Restraints
11.2.1 Effects of the Vioxx Issue
11.2.2 Reimbursement Issues and the Cost of Healthcare
11.2.3 Side Effects Limit the Narcotics Market
11.2.4 Under-Treatment of Pain
11.3 Concluding Remarks

12. Pipeline and Novel Products
12.1 Tanezumab
12.2 Ralfinamide
12.3 Nucynta (Tapentadol)
12.4 Abuse-Resistant Products
12.4.1 Remoxy
12.4.2 Embeda
12.5 COX-Inhibiting Nitric Oxide Donators
12.5.1 Naproxcinod
12.6 Improvements in Drug Delivery
12.6.1 Onsolis
12.6.2 Rapinyl/Abstral
12.6.3 Eladur
12.7 Cannabinoids - An Alternative to Opioids?
12.7.1 Sativex
12.8 Rx/Dx Tests

13. Geographical Breakdown of the Market
13.1 USA
13.2 The Mature European Market
13.3 Key Emerging Markets
13.3.1 China and India
13.3.2 Brazil
13.3.3 Russia and Eastern Europe
13.4 Concluding Remarks

14. Expert Opinions
14.1 Interview with Dr Anastasia Liapi (Astellas Pharma Europe)
14.1.1 On Assessing the Commercial Value of Novel Pain Therapies
14.1.2 On the Hurdles That Face New Launches in the Pain Market
14.1.3 On Geographical Differences
14.2 Interview with Dr William Schmidt (NorthStar Consulting LLC)
14.2.1 On the Growth of the Pain Market
14.2.2 On New Targets in Pain Management
14.2.3 On Unmet Needs in the Pain Market
14.2.4 On Regulatory Hurdles in the Post-Vioxx Era
14.2.5 On the Future of COX-2 Inhibitors

15. Conclusions
15.1 Growth
15.2 Market Dominance
15.3 Geographical Opportunities
15.4 OTC Issues

List of Tables
Table 3.1 Leading OTC Categories, Sales ($bn) and Market Share (%) 2008
Table 4.1 Leading Categories in the Analgesics Market, Sales ($m) and Market Share (%) 2008
Table 4.2 Blockbusters in the Analgesics Market, Sales ($m) and Market Share (%) 2008
Table 4.3 The Global Analgesics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 4.4 The OTC and Rx Arms of the Analgesics Market, Sales ($m) and Growth (%) 2008-2014
Table 5.1 Leading Companies in the Non-Narcotics and Anti-Pyretics Market, Sales ($m) and Market Share (%) 2008
Table 5.2 The Non-Narcotics and Anti-Pyretics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 6.1 Common Opioid Narcotics
Table 6.2 Geographical Breakdown of the Narcotics Market, Sales ($m) and Market Share (%) 2008
Table 6.3 Leading Companies in the Narcotics Market, Sales ($m) and Market Share (%) 2008
Table 6.4 The Narcotics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 7.1 The Anti-Rheumatics Pain Relief Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 8.1 Migraine Triggers
Table 8.2 Leading Companies in the Anti-Migraine Market, Sales ($m) and Market Share (%) 2008
Table 8.3 The Anti-Migraine Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 8.4 Patent Expiries in the Anti-Migraine Market
Table 9.1 The Anti-Epileptics Pain Relief Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 10.1 Top-Selling Local Anaesthetics ($m) 2008
Table 10.2 Leading Companies in the Local Anaesthetics Market, Sales ($m) and Market Share (%) 2008
Table 10.3 Geographical Breakdown of the Local Anaesthetics Market, Sales ($m) and Market Share (%) 2008
Table 10.4 The Local Anaesthetics Market, Sales ($m), Growth (%) and CAGR (%) 2008-2014, 2019, 2024
Table 11.1 SWOT Analysis of the Global Analgesics Market 2009-2024
Table 13.1 Geographical Breakdown of the Analgesics Market, Sales ($m), Market Share (%) and CAGR (%) 2008-2014, 2019, 2024

List of Figures
Figure 3.1 Leading OTC Categories, Market Share (%) 2008
Figure 4.1 Leading Categories in the Analgesics Market, Market Share (%) 2008
Figure 4.2 Blockbusters in the Analgesics Market, Market Share (%) 2008
Figure 4.3 The Global Analgesics Market, Sales ($m) 2008-2024
Figure 4.4 The OTC and Rx Arms of the Analgesics Market, Market Share (%) 2008-2014
Figure 5.1 Leading Companies in the Non-Narcotics and Anti-Pyretics Market, Market Share (%) 2008
Figure 5.2 Non-Narcotics and Anti-Pyretics Sales ($m) 2008-2024
Figure 5.3 Tylenol Sales ($m) 2008-2024
Figure 5.4 Advil Sales ($m) 2008-2024
Figure 5.5 Aspirin Bayer Sales ($m) 2008-2024
Figure 5.6 Panadol Sales ($m) 2008-2024
Figure 6.1 Geographical Breakdown of the Narcotics Market, Market Share (%) 2008
Figure 6.2 Leading Companies in the Narcotics Market, Market Share (%) 2008
Figure 6.3 Narcotics Sales ($m) 2008-2024
Figure 6.4 Oxycontin Sales ($m) 2008-2024
Figure 6.5 Duragesic Sales ($m) 2008-2024
Figure 6.6 Fentanyl Sales ($m) 2008-2024
Figure 7.1 Anti-Rheumatics Pain Relief Sales ($m) 2008-2024
Figure 7.2 Celebrex Sales ($m) 2008-2024
Figure 7.3 Voltaren Sales ($m) 2008-2024
Figure 7.4 Celebrex, Voltaren and Other Anti-Rheumatics, Sales ($m) 2008, 2014, 2019 and 2024
Figure 8.1 Leading Companies in the Anti-Migraine Market, Market Share (%) 2008
Figure 8.2 Anti-Migraine Sales ($m) 2008-2024
Figure 8.3 Imigran Sales ($m) 2008-2024
Figure 8.4 Maxalt Sales ($m) 2008-2024
Figure 9.1 Anti-Epileptics Pain Relief Sales ($m) 2008-2024
Figure 9.2 Lyrica Sales ($m) 2008-2024
Figure 9.3 Lyrica and Other Anti-Epileptics, Sales ($m) 2008, 2014, 2019 and 2024
Figure 10.1 Leading Companies in the Local Anaesthetics Market, Market Share (%) 2008
Figure 10.2 Geographical Breakdown of the Local Anaesthetics Market, Market Share (%) 2008
Figure 10.3 Local Anaesthetics Sales ($m) 2008-2024
Figure 10.4 Lidoderm Sales ($m) 2009-2024
Figure 10.5 Lidoderm and Other Local Anaesthetics, Sales ($m) 2008, 2014, 2019 and 2024
Figure 13.1 Geographical Breakdown of the Analgesics Market by Country, Sales ($m) 2009, 2014, 2019, 2024
Figure 13.2 Geographical Breakdown of the Analgesics Market, Market Share (%) 2008
Figure 13.3 Geographical Breakdown of the Analgesics Market, Market Share (%) 2024
Figure 13.4 European Analgesics Market, Sales ($m) 2009, 2014, 2019 and 2024
Figure 13.5 Emerging Analgesics Markets, Sales ($m) 2009, 2014, 2019 and 2024
Figure 13.6 Latin America Analgesics Market, Sales ($m) 2009, 2014, 2019 and 2024
Figure 13.7 Geographical Breakdown of the Analgesics Market by Region, Sales ($m) 2009, 2014, 2019, 2024

Companies Listed

Actavis
Abbott
Aguettant
Almirall
The American Pain Society
Apotex
Astellas Pharma
AstraZeneca
AZ Tika (AstraZeneca)
Bayer Pharmaceuticals
BioDelivery Sciences International
Boehringer Ingelheim
Bristol-Myers Squibb
The British Pain Society
The Center for Drug Evaluation and Research (CDER)
Dr. Reddy's Laboratories
The Drug Enforcement Administration (DEA)
Durect
Eisai
Eli Lilly
Endo Laboratories
The European Medicines Agency (EMEA)
Fresenius
Genentech (Roche)
GlaxoSmithKline
Gruenenthal
GW Pharmaceuticals
Hospira
Impax
The International Association for the Study of Pain
The International Headache Society
Ivax (Teva)
Johnson & Johnson
King Pharmaceuticals
KV Pharmaceutical
Kyorin
Lavipharm
Mallinckrodt
The Medicines and Healthcare products Regulatory Agency (MHRA)
Merck & Co
Mylan
Newron Pharmaceuticals
NicOx
NorthStar Consulting
Novartis
Orexo
Otsuka
Pfizer
The Pharmaceutical and Medical Devices Agency (PMDA)
Purdue/Mundipharma
Ranbaxy
Ratiopharm
Roche
Sanofi-Aventis
SkyePharma
Stada Healthcare
Taylor Nelson Sofres
Teva
UCB
The US Food and Drug Administration (FDA)
The US Society for Neuroscience
Valeant
Watson Pharmaceuticals
The World Health Organisation (WHO)
Wyeth

YOU MIGHT BE INTERESTED IN

Global Pain Relieving Drug Market Analysis 2010-2025

The Global Pain Market, 2008-2023

World Neurodegenerative Diseases Market 2009-2024

The World Dermatological Market Outlook 2010-2024

The World Antibacterial Treatments Market 2010-2024

The Global OTC Pharmaceutical Market 2009-2024

The Global Rheumatoid Arthritis Market Forecasts to 2012

REPORT

The Global Analgesics Market 2009-2024

Report Details

Table of Contents

Companies Listed